Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype
Maya Honda,
Masako Kataoka,
Mami Iima,
Rie Ota,
Akane Ohashi,
Ayami Ohno Kishimoto,
Kanae Kawai Miyake,
Marcel Dominik Nickel,
Yosuke Yamada,
Masakazu Toi,
Yuji Nakamoto
Affiliations
Maya Honda
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Kyoto 606-8507, Japan
Masako Kataoka
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Kyoto 606-8507, Japan
Mami Iima
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Kyoto 606-8507, Japan
Rie Ota
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Kyoto 606-8507, Japan
Akane Ohashi
Department of Translational Medicine, Diagnostic Radiology, Lund University, Skåne University Hospital, 205-02 Malmo, Sweden
Ayami Ohno Kishimoto
Department of Diagnostic Radiology, Kyoto Katsura Hospital, Yamadahirao-cho, Kyoto 615-8256, Japan
Kanae Kawai Miyake
Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Kyoto 606-8507, Japan
The purpose of this study was to investigate the diagnostic performance of ultrafast DCE (UF-DCE) MRI after the completion of neoadjuvant systemic therapy (NST) in breast cancer. In this study, MR examinations of 55 post-NST breast cancers were retrospectively analyzed. Residual tumor sizes were measured in the 20th phase of UF-DCE MRI, early and delayed phases of conventional DCE MRI, and high spatial-resolution CE MRI (UF, early, delayed, and HR, respectively). The diagnostic performance for the detection of residual invasive cancer was calculated by ROC analysis. The size difference between MRI and pathological findings was analyzed using the Wilcoxon signed-rank test with the Bonferroni correction. The overall AUC was highest for UF (0.86 and 0.88 for readers 1 and 2, respectively). The difference in imaging and pathological sizes for UF (5.7 ± 8.2 mm) was significantly smaller than those for early, delayed, and HR (p p < 0.01). UF-DCE MRI demonstrated higher AUC and specificity for the more accurate detection of residual cancer and the visualization of tumor extent than conventional DCE MRI.